autologous anti-CD20 CAR T cells

Autologous anti-CD20 CAR T cells are a form of cell therapy in which a patient's own (autologous) T lymphocytes are genetically modified ex vivo to express a chimeric antigen receptor (CAR) that specifically targets the CD20 antigen, which is highly expressed on the surface of B-cell malignancies such as non-Hodgkin lymphoma and mantle cell lymphoma. The engineered CAR typically consists of an extracellular single-chain variable fragment (scFv) derived from an antibody against CD20, fused to intracellular signaling domains such as CD28 and/or 4-1BB for costimulation, and CD3ζ for activation. Upon reinfusion into the patient, these modified T cells recognize and kill CD20-expressing tumor cells through targeted cytotoxicity. This approach is being investigated primarily in relapsed or refractory B-cell lymphomas but is also under exploration for autoimmune diseases due to its ability to deplete pathogenic B-cells[1][2][5][10].

Other names

autologous anti-CD20 CAR T cellsautologous anti-CD20CAR-CD28-4-1BB-CD3zeta T lymphocytesanti-CD20 CAR T cellsanti-CD-20 CAR T cellsanti-CD 20 CAR T cells